SAREPTA THERAPEUTICS, INC. Q2 2019 EARNINGS CONFERENCE CALL
FORWARD-LOOKING STATEMENTS

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, priorities and research and development programs including: a PDUFA date of August 19 for golodirsen, a potential approval for golodirsen on August 19 and our readiness to launch immediately upon approval; our intention to submit casimersen for FDA review in 2019, with an approval decision expected in the first half of 2020; the potential to replicate our success and treat greater segments of the Duchenne population; the benefits of our product, product candidates and programs, including the potential of our micro-dystrophin program to be a transformative treatment that can battle DMD effectively; our plan to develop and launch 3 internally developed therapies by early 2020 and to more than double the number of DMD patients who have an available PMO therapy; our goal to obtain dosing and safety insight from our multi-ascending dose study for SRP 5051 by the first half of 2020; our estimation re the micro-dystrophin program's probability of success; our plans and expectations regarding our micro-dystrophin program, including to increase the N of Study 2 in SRP-9001 to 40 patients to further improve the powering of our current placebo trial and enhance the probability of success, to open another U.S. clinical trial site in the near term, to complete enrollment in Q4 2019, to have a read out of Study 2 before the end of 2020, to commence Study 3 in the first half 2020 and to have 3-month biopsy data from Study 3 by the read out of Study 2, to provide sufficient evidence to continue to improve process and yields, to achieve optimized yields in the commercial ICellis500 units, our goal to be in a position to satisfy, alone, the requirements of the DMD community we serve, and the possibility of Sarepta launching a micro-dystrophin gene therapy alone or at significant advantage; the goals and design of our studies; our plan to dose one additional LGMD2E 3-patient dose escalation cohort this year; our plan to chart out a pathway for all 5 of the LGMD programs from Myonexus and to report that out early next year; our plan to commence dosing before the end of the year in our CMT program at NCH; our hiring plans; Sarepta being positioned for long-term growth; our expectation to continue to invest in building our pipeline and in adding technologies in areas currently in our pipeline; our goal to treat all eligible individuals with Duchenne; our plan to leverage our current distribution partners and our SareptaAssist network to help get patients access to VYONDYS 53 as soon as possible; the expected access to VYONDYS 53, the expected commercial to Medicaid patient mix and the expected rate of transition from hospital to home infusion; the potential of EXONDYS 51, VYONDYS 53 and casimersen to treat 13%, 8% and 8% of the DMD population, respectively; our commercial readiness plans with respect to golodirsen, casimersen and our gene therapy programs; our goal to reach patients as soon as possible following approval of VYONDYS 53; our global expansion plans; and Sarepta being ready for future potential launches.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to EXONDYS 51 sales or attain the anticipated net revenues, profitability or positive cash-flow from operations; we may not be able to comply with FDA post-approval commitments and requirements with respect to EXONDYS 51 in a timely manner or at all; the expected benefits and opportunities related to our collaborations with strategic partners may not be realized or may take longer to realize; Sarepta's dependence on certain manufacturers to produce its product candidates, including Sarepta's inability to accurately anticipate product demand and timely secure manufacturing capacity, may impair the availability of product to successfully support various programs; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and initial results from a clinical trial do not necessarily predict final results; our data for golodirsen, casimersen, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; if the actual number of patients suffering from the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; current reimbursement models may not accommodate the unique factors of our gene therapy product candidates; Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of Sarepta's control, including possible limitations of company financial and other resources, manufacturing limitations, reimbursement hurdles and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta's product candidates; and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K for the year ended December 31, 2018 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.